quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:22·10d
SECFiling
Kalaris Therapeutics Inc. logo

SEC Form EFFECT filed by Kalaris Therapeutics Inc.

KLRS· Kalaris Therapeutics Inc.
Health Care
Original source

Companies

  • KLRS
    Kalaris Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 16UpdateMorgan Stanley$14.00
  • Dec 23UpdateChardan Capital Markets$19.00
  • Nov 3UpdateCitizens JMP$20.00
  • Sep 3UpdateRaymond James$23.00
  • Jul 23UpdatePiper Sandler$3.00
  • May 7UpdateLeerink Partners$20.00

Related

  • ANALYST7d
    Morgan Stanley initiated coverage on Kalaris Therapeutics with a new price target
  • SEC10d
    SEC Form EFFECT filed by Kalaris Therapeutics Inc.
  • SEC10d
    SEC Form 424B3 filed by Kalaris Therapeutics Inc.
  • SEC10d
    SEC Form 424B3 filed by Kalaris Therapeutics Inc.
  • SEC13d
    SEC Form 8-K filed by Kalaris Therapeutics Inc.
  • SEC20d
    SEC Form S-3 filed by Kalaris Therapeutics Inc.
  • SEC20d
    SEC Form S-3 filed by Kalaris Therapeutics Inc.
  • INSIDER31d
    SEC Form 4 filed by Hagen Brett R
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022